The presence of NPM1 mutations in AML appears to enhance responsiveness to PD-1-based immunotherapies, suggesting that the underlying genetic alterations of the disease might critically influence the effectiveness of checkpoint blockade [156,157]. This evidence concerns the gene PDCD1 and acute myeloid leukemia.